BridgeBio Pharma Competitors

BeiGene (NASDAQ:BGNE) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

60.7% of BeiGene shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 9.0% of BeiGene shares are held by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for BeiGene and BridgeBio Pharma, as reported by MarketBeat.com.

BeiGene currently has a consensus target price of $319.3750, indicating a potential upside of 3.76%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than BeiGene.

Valuation & Earnings

This table compares BeiGene and BridgeBio Pharma's gross revenue, earnings per share and valuation.

BridgeBio Pharma has lower revenue, but higher earnings than BeiGene. BridgeBio Pharma is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BeiGene and BridgeBio Pharma's net margins, return on equity and return on assets.

Volatility and Risk

BeiGene has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Summary

BridgeBio Pharma beats BeiGene on 9 of the 14 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and BridgeBio Pharma (NASDAQ:BBIO) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Royalty Pharma and BridgeBio Pharma's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Royalty Pharma and BridgeBio Pharma's gross revenue, earnings per share and valuation.

Royalty Pharma has higher earnings, but lower revenue than BridgeBio Pharma.

Analyst Recommendations

This is a breakdown of recent recommendations for Royalty Pharma and BridgeBio Pharma, as reported by MarketBeat.com.

Royalty Pharma currently has a consensus target price of $51.8750, indicating a potential upside of 24.55%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Royalty Pharma.

Summary

BridgeBio Pharma beats Royalty Pharma on 6 of the 8 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

6.2% of Genmab A/S shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Genmab A/S and BridgeBio Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Genmab A/S and BridgeBio Pharma's revenue, earnings per share (EPS) and valuation.

Genmab A/S has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Genmab A/S and BridgeBio Pharma, as provided by MarketBeat.com.

Genmab A/S presently has a consensus target price of $42.1429, indicating a potential upside of 20.48%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Genmab A/S.

Volatility & Risk

Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Summary

Genmab A/S beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Horizon Therapeutics Public and BridgeBio Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Horizon Therapeutics Public and BridgeBio Pharma's revenue, earnings per share (EPS) and valuation.

Horizon Therapeutics Public has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Horizon Therapeutics Public and BridgeBio Pharma, as provided by MarketBeat.com.

Horizon Therapeutics Public presently has a consensus target price of $111.3636, indicating a potential upside of 19.09%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Horizon Therapeutics Public.

Volatility & Risk

Horizon Therapeutics Public has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats BridgeBio Pharma on 10 of the 14 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

4.3% of CureVac shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares CureVac and BridgeBio Pharma's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares CureVac and BridgeBio Pharma's revenue, earnings per share (EPS) and valuation.

CureVac has higher earnings, but lower revenue than BridgeBio Pharma.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for CureVac and BridgeBio Pharma, as provided by MarketBeat.com.

CureVac presently has a consensus target price of $58.3333, indicating a potential downside of 43.94%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than CureVac.

Summary

BridgeBio Pharma beats CureVac on 6 of the 8 factors compared between the two stocks.

Catalent (NYSE:CTLT) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Earnings & Valuation

This table compares Catalent and BridgeBio Pharma's revenue, earnings per share (EPS) and valuation.

Catalent has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Catalent and BridgeBio Pharma, as provided by MarketBeat.com.

Catalent presently has a consensus target price of $125.1250, indicating a potential upside of 12.74%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 32.65%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Catalent.

Insider & Institutional Ownership

97.8% of Catalent shares are held by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are held by institutional investors. 1.0% of Catalent shares are held by insiders. Comparatively, 40.3% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Catalent and BridgeBio Pharma's net margins, return on equity and return on assets.

Volatility & Risk

Catalent has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Summary

Catalent beats BridgeBio Pharma on 9 of the 14 factors compared between the two stocks.